C4 Therapeutics Inc at Jefferies Healthcare Conference (Virtual) Transcript
Good morning, everyone. My name is Kelly Shi, one of the biotech analysts at Jefferies. Thank you for attending our virtual healthcare conference. We are very pleased to have C4 Therapeutics team, Mr. Andrew Hirsch, President and the CEO; Mr. Adam Crystal, CMO; and Mr. Stewart Fisher, CSO, join our fireside chat session.
C4 Therapeutics is a pioneer in targeted protein degrader technology, which is a broader concept than [PROTAC]. And this is a technology -- we can also call it a space now, as of today, has attracted a lot of attention from pharma and the biotech industry.
Andrew, maybe you can share with us your insights. What makes TPD a promising and appealing technology among all of the therapeutic modalities such as the small molecule inhibitors, antibodies, or even RA interferons?
Sure. Thanks, Kelly, [for introducing] us. So, you are right. It is a really exciting field and we are really excited to be a leader in this field. I think what is
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
